Cancer Cell:研究人员成功消灭肿瘤干细胞

2013-03-25 蓝建中 新华社

日本一个研究小组发现,对肿瘤干细胞进行基因操作可以使化疗药物更易发挥作用,杀死癌细胞。这一发现或促进开发出根治癌症的治疗方法。 肿瘤干细胞被认为在体内处于几乎不增殖的“休眠状态”。化疗药物虽能遏制肿瘤细胞增殖,但对干细胞却难以发挥作用。即使化疗后肿瘤看起来已经消失,但只要残留少量干细胞,就会导致癌症复发和转移。 日本九州大学教授中山敬一率领的研究小组发现,肿瘤干细胞中一种名为“Fbxw7”蛋白


日本一个研究小组发现,对肿瘤干细胞进行基因操作可以使化疗药物更易发挥作用,杀死癌细胞。这一发现或促进开发出根治癌症的治疗方法。

肿瘤干细胞被认为在体内处于几乎不增殖的“休眠状态”。化疗药物虽能遏制肿瘤细胞增殖,但对干细胞却难以发挥作用。即使化疗后肿瘤看起来已经消失,但只要残留少量干细胞,就会导致癌症复发和转移。

日本九州大学教授中山敬一率领的研究小组发现,肿瘤干细胞中一种名为“Fbxw7”蛋白质能够遏制细胞分裂。他们对患有慢性骨髓性白血病的实验鼠进行基因操作,使肿瘤干细胞无法再制造这种蛋白质。此后,研究人员让实验鼠服用化疗药物“格列卫”,35天后不再给药。

研究发现,一般情况下,患白血病的实验鼠60天后会有90%的复发率,而不能制造“Fbxw7”蛋白质的实验鼠复发率只有20%左右。研究小组判断肿瘤干细胞已经死亡。

中山敬一说:“如果开发出阻碍这种蛋白质发生作用的药物,同时与化疗药物并用,就有望根治癌症。”相关研究成果刊登在美国《癌细胞》(Cancer Cell )杂志网络版上。

肿瘤干细胞相关的拓展阅读:

doi:10.1016/j.ccr.2013.01.026

Ablation of Fbxw7 Eliminates Leukemia-Initiating Cells by Preventing Quiescence

Shoichiro Takeishi, Akinobu Matsumoto, Ichiro Onoyama, Kazuhito Naka, Atsushi Hirao, Keiichi I. Nakayama.

Imatinib eradicates dividing progenitor cells of chronic myeloid leukemia (CML) but does not effectively target nondividing leukemia-initiating cells (LICs); thus, the disease often relapse after its discontinuation. We now show that Fbxw7 plays a pivotal role in maintenance of quiescence in LICs of CML by reducing the level of c-Myc. Abrogation of quiescence in LICs by Fbxw7 ablation increased their sensitivity to imatinib, and the combination of Fbxw7 ablation with imatinib treatment resulted in a greater depletion of LICs than of normal hematopoietic stem cells in mice. Purging of LICs by targeting Fbxw7 to interrupt their quiescence and subsequent treatment with imatinib may thus provide the basis for a promising therapeutic approach to CML.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780601, encodeId=05fa1e80601dc, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 06 22:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868634, encodeId=e612186863452, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 23 13:36:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958868, encodeId=e59a195886804, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Dec 11 19:36:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907416, encodeId=a368190e416ef, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Sep 08 15:36:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780601, encodeId=05fa1e80601dc, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 06 22:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868634, encodeId=e612186863452, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 23 13:36:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958868, encodeId=e59a195886804, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Dec 11 19:36:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907416, encodeId=a368190e416ef, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Sep 08 15:36:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780601, encodeId=05fa1e80601dc, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 06 22:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868634, encodeId=e612186863452, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 23 13:36:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958868, encodeId=e59a195886804, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Dec 11 19:36:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907416, encodeId=a368190e416ef, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Sep 08 15:36:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
    2013-12-11 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780601, encodeId=05fa1e80601dc, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 06 22:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868634, encodeId=e612186863452, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 23 13:36:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958868, encodeId=e59a195886804, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Dec 11 19:36:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907416, encodeId=a368190e416ef, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Sep 08 15:36:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]

相关资讯

CA Cancer J Clin:Oncotype DX HER2检查结果不能作为乳腺癌治疗方案的决策标准

美国匹兹堡大学的研究者日前评估了Oncotype DX检查中观察到的人类表皮生长因子受体2(HER2)状态与免疫组织化学(IHC)和荧光原位杂交(FISH) 确定的HER2状态之间的一致性(J Clin Oncol. 2011;29:4279-4285)。他们的数据显示指南指定的IHC 和FISH联合方案确定的相当数量的HER2阳性乳腺癌病例中,用Oncotype DX检查往往得出HER2假阴性的

Diabetologia:乳腺癌幸存者更易患糖尿病

       一项新研究表明绝经后乳腺癌幸存者比未患乳腺癌者更容易患糖尿病。此外,乳腺癌和糖尿病之间之间的关系会有所不同,这取决于是否乳腺癌幸存者经历了化疗。相关研究结果发表在2012年12月13日的Diabetologia杂志上。        糖尿病和癌症之间有关联越来越被大家认可。例如,糖尿病妇女患乳腺

FDA:批准阿比特龙用于mCRPC一线解救治疗

       美国食品和药物管理局(FDA)批准扩大使用醋酸阿比特龙(Zytiga,杨森生物技术公司)用于转移性激素抵抗性前列腺癌(mCRPC)的一线解救治疗。这个降低睾丸激素产生的药物,已于2011年4月被批准作为多西紫杉醇化疗后的二线治疗药物用于上述患者。       “目前这种

SABCS:乳腺癌内分泌治疗的3项重磅研究

       作者:军事医学科学院附属医院乳腺肿瘤科 王涛        在今年美国圣安东尼奥乳腺癌会议(SABCS)举办的首日,继开篇大会报告——《激素与乳腺癌》之后,乳腺癌内分泌治疗专场上演。本专场重点公布了3项临床研究的结果,特别是ATLAS研

JNCI :质子放射治疗可以将前列腺癌患者的副作用降到很低水平

耶鲁大学医学院的研究人员在国家癌症研究所的杂志上报告,与接受标准放射治疗[名为调强放疗(IMRT)]的患者相比,接受质子放疗(费用高昂)的患者的副作用,例如尿失禁和勃起功能障碍能缓解到最低程度。 众所周知,男性前列腺癌的标准治疗—根治性前列腺切除术和调强放疗—会导致尿失禁和勃起功能障碍之类的副作用。质子放射治疗的支持者认为,质子的物理性质可能减少这些常见的副作用。 “质子放射治疗变得越来越普及

SABCS:他汀类药物或可改善炎性乳腺癌PFS

       一项大规模的回顾性研究显示:有他汀类药物服用史的炎性乳腺癌患者的肿瘤生长更为缓慢。        在第35届圣安东尼奥乳腺癌论坛(SABCS)上,来自美国德克萨斯大学MD安德森癌症中心的Naoto Ueno博士表示:他汀类药物的使用可显著改善炎性乳腺癌患者的无进展生存期(PFS),分析不同类型的